The Protocol Review Committee (PRC) is a multi-disciplinary committee whose mission is to provide scientific review for all clinical protocols involving cancer patients at the University of Iowa Hospitals and Clinics, or UICC resources. This review includes any protocol that: 1) involves patients seen in the John and Marry Pappajohn Clinical Cancer Center or cancer patients from other units in the hospital such as the Bone Marrow Transplantation Unit, Radiation Therapy, the General Clinical Research Center, and the Oncology ward of the Children's Hospital of Iowa or 2) uses UICC resources such as the Core facilities. The role of the PRC is complementary to that of the IRB The PRC is complementary to that of the IRB. The PRC ensures that 1) institutional protocols have adequate scientific rationale to justify the hypothesis, 2) experimental design is rational and includes a clearly stated valid statistical section, a realistic assessment of accrual and appropriate response parameters, 3) the scientific question to be answered is of sufficient interest to justify use of UICC resources, 4) investigators have considered all potential basic science correlates that might be pursued as part of their studies, and 5) studies are prioritized that deal with similar patient populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-03
Application #
6658349
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-07-01
Project End
2003-06-30
Budget Start
Budget End
Support Year
3
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Thompson, Carrie A; Yost, Kathleen J; Maurer, Matthew J et al. (2018) Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol 36:749-756
Brandt, Kristin E; Falls, Kelly C; Schoenfeld, Joshua D et al. (2018) Corrigendum to: Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells [Redox Biol. (2018) 82-87]. Redox Biol :
Ding, George X; Alaei, Parham; Curran, Bruce et al. (2018) Image guidance doses delivered during radiotherapy: Quantification, management, and reduction: Report of the AAPM Therapy Physics Committee Task Group 180. Med Phys 45:e84-e99
Wilkes, Justin G; O'Leary, Brianne R; Du, Juan et al. (2018) Pharmacologic ascorbate (P-AscH-) suppresses hypoxia-inducible Factor-1? (HIF-1?) in pancreatic adenocarcinoma. Clin Exp Metastasis 35:37-51
Sweeney, Sean K; Manzar, Gohar S; Zavazava, Nicholas et al. (2018) Tracking embryonic hematopoietic stem cells to the bone marrow: nanoparticle options to evaluate transplantation efficiency. Stem Cell Res Ther 9:204
Alexander, Matthew S; O'Leary, Brianne R; Wilkes, Justin G et al. (2018) Enhanced Pharmacological Ascorbate Oxidation Radiosensitizes Pancreatic Cancer. Radiat Res :
Ghahramani, Grant K; Goetz, Kirsten E; Liu, Vincent (2018) Dermoscopic characterization of cutaneous lymphomas: a pilot survey. Int J Dermatol 57:339-343
Jorgensen, Jeffery B; Smith, Russell B; Coughlin, Andrew et al. (2018) Impact of PET/CT on Staging and Treatment of Advanced Head and Neck Squamous Cell Carcinoma. Otolaryngol Head Neck Surg :194599818794479
Jain, Rohit K; Snyders, Travis; Nandgoapal, Lakshminarayanan et al. (2018) Immunotherapy Advances in Urothelial Carcinoma. Curr Treat Options Oncol 19:79
Guseva, Natalya V; Jaber, Omar; Stence, Aaron A et al. (2018) Simultaneous detection of single-nucleotide variant, deletion/insertion, and fusion in lung and thyroid carcinoma using cytology specimen and an RNA-based next-generation sequencing assay. Cancer Cytopathol 126:158-169

Showing the most recent 10 out of 1080 publications